Q2 Solutions verruimt capaciteit voor diagnostiek met samenwerking Illumina
MORRISVILLE, N.C.–(BUSINESS WIRE)– Q2 Solutions, een internationale verlener van laboratoriumdiensten voor klinisch onderzoek, heeft vandaag bekendgemaakt dat zijn capaciteiten op vlak van genomische diagnostiek voor veilige medicijntoediening (companion diagnostics, CDx) zijn verruimd. Dit is het resultaat van een overeenkomst tussen Q2 Solutions – EA Genomics en het internationaal toonaangevende Illumina. De partijen werken aan een kader voor de ontwikkelingen van CDx-tests op basis van vernieuwde methodes voor sequencing. De uitbreiding van Q 2 Solutions’ portfolio voor CDx-ontwikkeling verbetert de dienstverlening van het bedrijf. De diensten variëren van onderzoek naar biomarkeerders en de ontwikkeling daarvan tot de toepassing van precieze geneeskunde via het netwerk van laboratoria voor klinisch onderzoek.
Q2 Solutions Enhances Companion Diagnostics Capabilities in Collaboration with Illumina |
|||||
|
MORRISVILLE, N.C.–(BUSINESS WIRE)– Q 2 Solutions, a global clinical trials laboratory services organization, today announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q 2 Solutions – EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q 2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024005159/en/ Under the terms of the agreement, Q 2 Solutions will develop NGS assays using the Illumina MiSeqDx® instrument. The MiSeqDx is the first NGS instrument to be cleared by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic purposes in clinical laboratories. This alliance brings together two industry-leading companies, combining Q 2 Solutions’ global experience and local knowledge, as well as its deep genomic, scientific and medical expertise, with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function. “At Q 2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world,” said Costa Panagos, chief executive officer, Q 2 Solutions. “The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical. Q 2 Solutions helped develop 62 percent of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.” To hear more about this opportunity, view this video featuring Kellie Yarnell, vice president of Genomics Laboratories, Q 2 Solutions. About Q 2 Solutions, a Quintiles Quest joint venture Launched in 2015, Q 2 Solutions is a global clinical trials laboratory services organization that helps biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q 2 Solutions is a joint venture formed by QuintilesIMS and Quest Diagnostics, combining the clinical trials laboratory services of each parent organization. To learn more, visit www.q2labsolutions.com. Click here to subscribe to Mobile Alerts for QuintilesIMS. View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005159/en/ Contacts QuintilesIMS |
|||||